These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Construction of transgenic mouse system expressing human islet amyloid polypeptide (IAPP)/amylin]. Yagui K; Kanatsuka A; Makino H Nihon Rinsho; 1994 Oct; 52(10):2746-50. PubMed ID: 7983808 [TBL] [Abstract][Full Text] [Related]
3. Severe insulin resistance associated with subcutaneous amyloid deposition. Albert SG; Obadiah J; Parseghian SA; Yadira Hurley M; Mooradian AD Diabetes Res Clin Pract; 2007 Mar; 75(3):374-6. PubMed ID: 16930758 [TBL] [Abstract][Full Text] [Related]
4. [Role of IAPP in the pathogenesis and development of NIDDM]. Sanke T; Nishi M; Nanjo K Nihon Rinsho; 1994 Oct; 52(10):2737-45. PubMed ID: 7983807 [TBL] [Abstract][Full Text] [Related]
6. [New prospects for the type 2 diabetic patient. Delaying disease progression]. MMW Fortschr Med; 2000 Nov; 142(46):56-7. PubMed ID: 11138590 [No Abstract] [Full Text] [Related]
7. What nurses don't know about managing NIDDM. Wilson BA Medsurg Nurs; 1994 Apr; 3(2):152-4. PubMed ID: 8173627 [No Abstract] [Full Text] [Related]
8. [Development of prediction for NIDDM from a view point of genetics]. Sanke T Nihon Rinsho; 1997 Nov; 55 Suppl():362-8. PubMed ID: 9434495 [No Abstract] [Full Text] [Related]
9. [Chronic inflammation can cause type 2 diabetes]. Sjöholm A; Nyström T Lakartidningen; 2004 May; 101(19):1716-21. PubMed ID: 15188586 [No Abstract] [Full Text] [Related]
10. [Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early]. MMW Fortschr Med; 2000 Nov; 142(47):56. PubMed ID: 11143782 [No Abstract] [Full Text] [Related]
12. Early use of insulin for beta cell preservation. Kumar A J Assoc Physicians India; 2007 Jul; 55 Suppl():26-8. PubMed ID: 17927008 [No Abstract] [Full Text] [Related]
13. Initiating insulin in type 2 diabetes. Ravina A Isr Med Assoc J; 2004 Dec; 6(12):787. PubMed ID: 15609901 [No Abstract] [Full Text] [Related]
14. [Amylin and amyloidosis of the pancreatic islets and their significance in the etiology and pathogenesis of diabetes mellitus type 2]. Kamaeva OI Ter Arkh; 1993; 65(10):14-7. PubMed ID: 8296225 [No Abstract] [Full Text] [Related]
15. Insulin therapy for type 2 diabetes. Pergallo-Dittko V Diabetes Self Manag; 2003; 20(5):17, 21, 23-4. PubMed ID: 14679948 [No Abstract] [Full Text] [Related]
16. Oral hypoglycaemic agents in the treatment of immunogenic insulin resistance in NIDDM. Ramachandran A; Snehalatha C; Mohan V; Rao CA; Viswanathan M Diabete Metab; 1987 Apr; 13(2):140-1. PubMed ID: 3595969 [No Abstract] [Full Text] [Related]
17. The nature of type 2 diabetes: the role for new agents. Taylor R Int J Clin Pract Suppl; 1999 Jul; 104():14-7; discussion 18-20. PubMed ID: 12669733 [No Abstract] [Full Text] [Related]
18. Oral hypoglycemic agents. Lebovitz HE Prim Care; 1988 Jun; 15(2):353-69. PubMed ID: 3290924 [TBL] [Abstract][Full Text] [Related]
20. Fate of the beta-cell in the pathophysiology of type 2 diabetes. Campbell RK J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]